In another study, Han et al. [15], observed a 60 % incidence of EGFR mutations in NSCLC brain metastases; however, this study was based on a small patient cohort including five NSCLC patients with primary and corresponding brain tumours. This evidence concerns the gene EGFR and non-small cell lung carcinoma.